Responses
Psoriatic arthritis
Original research
Secukinumab improves physical function and quality of life and inhibits structural damage in patients with PsA with sustained remission or low disease activity: results from the 2-year phase 3 FUTURE 5 study
Compose a Response to This Article
Other responses
No responses have been published for this article.